Business
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverageCommenced commercial sales of Lisaftoclax in China, following approval on July 10, 2025 by China’s NMPA for the treatment of adult patients with CLL/SLL who have previously received at least one systemic therapy including BTK inhibitorsRegistrational Phase III trial for 1L HR MDS (GLORA-4) cleared by FDA and EMA, a
About this update from Ascentage Pharma Group International
[{"type":"image","alt":"ASCENTAGE PHARMA GROUP INTERNATIONAL","displaySize":"","headline":null,"caption":"ASCENTAGE PHARMA GROUP INTERNATIONAL","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/08e2ffb35cd6ca4b1993dc7253b2f226"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_IJsL001nxkbUKUGjfvIgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/08e2ffb35cd6ca4b1993dc7253b2f226","width":300,"height":113}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverage","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"Commenced commercial sales of Lisaftoclax in China, following approval on July 10, 2025 by China’s NMPA for the treatment of adult patients with CLL/SLL who have previously received at least one systemic therapy including BTK inhibitors","length":236,"tagName":"p"}]},{"val":[{"type":"text","content":"Registrational Phase III trial for 1L HR MDS (GLORA-4) cleared by FDA and EMA, and first patients enrolled in Europe and China","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed a top-up placement in July 2025, resulting in US$190.1 million in net proceeds","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Nine registrational clinical trials are in progress, including three cleared by FDA","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Chinese (Mandarin) language investor webcast at 9:00 pm EDT on August 20, 2025 / 9:00 am HKT on August 21, 2025, and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 21, 2025","length":198,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":920,"olType":false},{"type":"text","content":"ROCKVILLE, Md. and SUZHOU, China, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as “Ascentage Pharma,” the “Company,” “we,” “us” or “our”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address un...